ArticleCancer research2020
Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 38 citations in OpenAlex.
- Cryo-EM structure-based discovery of etravirine as a specific inhibitor of PRMT5/pICln protein-protein interaction for prostate cancer treatment.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities.Journal of biomedical science · 2026Review
- Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors.Genes & diseases · 2026Review
- Protein arginine methyltransferase 7 regulates the cell cycle and promotes the progression of prostate cancer.Oncology letters · 2025Article
- Genomic features of the methylosome protein MEP50 and its implications in hormone signaling and cancer.Endocrine connections · 2025Article
- Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma.International journal of translational medicine (Basel, Switzerland) · 2025Article
- PRMT5:MEP50 Are Mediators of Treatment-Induced Neuroendocrine Differentiation in Prostate Cancer.The Prostate · 2025Article
- CLNS1A regulates genome stability and cell cycle progression to control CD4 T cell function and autoimmunity.Science immunology · 2025Article
- Identification of a Selective Cell-Active Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) for the Treatment of Prostate Cancer by Structure-Based Virtual Screening.Chemical biology & drug design · 2025Article
- Virtual High-Throughput Screening of Ligands for Disrupting PRMT5/pICLn Interaction in Prostate Cancer Cells.ACS medicinal chemistry letters · 2025Article
- Discovery of a Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader.Journal of medicinal chemistry · 2025Article
- Targeting ADAR1 with a small molecule for the treatment of prostate cancer.Nature cancer · 2025Article
- Discovery of PRMT5 N-Terminal TIM Barrel Ligands from Machine-Learning-Based Virtual Screening.ACS omega · 2025Article
- UnveilingBiomedicines · 2024Article
- PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression.The Journal of clinical investigation · 2024Article
- Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.Frontiers in endocrinology · 2024Review
- Review
- Emerging proteins involved in castration‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review).International journal of oncology · 2023Review
- PRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC.Thoracic cancer · 2023Article
- The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with the snRNP biogenesis machinery.Oncogene · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Elena BeketovaDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-0654-9083
Shuyi Fang *Department of BioHealth Informatics, Indiana University School of Informatics and Computing, Indiana University - Purdue University Indianapolis, Indianapolis, Indiana.ORCID 0000-0002-8645-5377
Jake L Owens *Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-7359-5338
Sheng LiuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana.
Xufeng ChenDepartment of Pathology, Duke University School of Medicine, Durham, North Caroline.
Qingfu ZhangDepartment of Pathology, Duke University School of Medicine, Durham, North Caroline.
Andrew M AsberryDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0001-8277-2810
Xuehong DengDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.
Jonathan MalolaDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.
Jiaoti HuangDepartment of Pathology, Duke University School of Medicine, Durham, North Caroline.
Chenglong LiDepartment of Medicinal Chemistry, University of Florida College of Pharmacy, Gainesville, Florida.
Roberto PiliDepartment of Medical Oncology, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana.
Bennett D ElzeyDepartment of Comparative Pathobiology, Purdue University, West Lafayette, Indiana.
Timothy L RatliffDepartment of Comparative Pathobiology, Purdue University, West Lafayette, Indiana.ORCID 0000-0003-4221-5416
Jun WanDepartment of BioHealth Informatics, Indiana University School of Informatics and Computing, Indiana University - Purdue University Indianapolis, Indianapolis, Indiana. hu1@purdue.edu junwan@iu.edu.
Chang-Deng HuDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana. hu1@purdue.edu junwan@iu.edu.
Purdue University West Lafayette · USDuke University · USIndiana University Health · USUniversity of Florida · USUniversity of Indianapolis · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8MTumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3MTransgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4MQuality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2MIndiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3MRole and targeting of PRMT5 in prostate cancerR01CA212403 · NCI · PURDUE UNIVERSITY · PI HU, CHANG-DENG, HUANG, JIAOTI · 2017 to 2021
$3.0MNRSA Training CoreTL1TR002531 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI FOTI, DANIEL JUSTIN, HURLEY, THOMAS D. · 2018 to 2022
$2.5MIndiana Clinical and Translational Sciences InstituteTL1TR001107 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$2.0MPurdue Drug Discovery Training ProgramT32GM125620 · NIGMS · PURDUE UNIVERSITY · PI DYKHUIZEN, EMILY CARLA, WEI, ALEXANDER · 2019 to 2023
$891kNCATS NIH HHS TL1 TR001107NCATS NIH HHS TL1 TR002531NCATS NIH HHS UL1 TR001108NCATS NIH HHS UL1 TR002529NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA023168NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA212403NIGMS NIH HHS T32 GM125620
Abstract
The majority of advanced prostate cancer therapies aim to inhibit androgen receptor (AR) signaling. However, AR reactivation inevitably drives disease progression to castration-resistant prostate cancer (CRPC). Here we demonstrate that protein arginine methyltransferase 5 (PRMT5) functions as an epigenetic activator of
Indexed as
Adaptor Proteins, Signal TransducingAnimalsCell EnlargementDisease ProgressionDown-RegulationEpigenesis, GeneticGene Expression ProfilingGene Knockdown TechniquesHeterograftsHumansIon ChannelsMaleMethylationMiceNeoplasm TransplantationPromoter Regions, GeneticAdaptor Proteins, Signal TransducingAR protein, humanCLNS1A protein, humanIon ChannelsPRMT5 protein, humanProtein-Arginine N-MethyltransferasesReceptors, AndrogenReceptors, Histamine H2Receptors, Histamine H3Transcription FactorsWDR77 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.